| Literature DB >> 26989068 |
Cornelia Ottiger1, Nicole Gygli1, Andreas R Huber1, Beatriz Fernandez-Tresguerres2, Scott Pardo3, Thorsten Petruschke4.
Abstract
This study assesses and demonstrates that CONTOUR® XT-BGMS (CXT-BGMS) complies with the requirements of the German (RiliBÄK) and Swiss (QUALAB) quality control guidelines for point-of-care testing (POCT) and fulfills the ISO15197:2013 accuracy limits criteria under the routine conditions of a hospital point-of care setting. This single-center study was conducted in Switzerland using 105 venous blood samples from hospitalized patients. Each sample was tested in comparison to the hexokinase reference method. Compliance with POCT guidelines was assessed by daily BGMS measurements using control solutions. Accuracy of CXT-BGMS according to ISO limits was 98.41%. All control measurements were within the limits defined by RiliBÄK (within ± 11% of target values and root mean square error [RMSE] within RMSE limits), and QUALAB (within ± 10% of target values).Entities:
Keywords: BGMS; Contour XT; ISO 15197; POCT; QUALAB; RiliBÄK
Mesh:
Substances:
Year: 2016 PMID: 26989068 PMCID: PMC4928233 DOI: 10.1177/1932296816638854
Source DB: PubMed Journal: J Diabetes Sci Technol ISSN: 1932-2968